Oral therapies for human microbiome modulation

Vedanta Biosciences is creating a new class of drugs to modulate the human microbiome. The foundation invested in the company to develop new interventions and therapeutics based on bacterial consortia for the treatment of enteric disease and childhood stunting in the developing world.
  • Domain
  • Investment type
    Direct equity
  • Status
  • Initial investment
    Series C-2
  • Partnered in
  • Investment lead
    Chris Chen
  • Headquarters
  • Program strategy
    Maternal & Newborn Child Health

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.